Human leukocyte antigen A*03:01 (HLA-A*03:01) (HLA-A*03:01)

HLA-A*03:01 is a specific allele of the Human Leukocyte Antigen (HLA) class I A gene, belonging to the HLA-A3 supertype. It encodes a cell surface glycoprotein that plays a critical role in the adaptive immune system by presenting intracellularly derived peptides to CD8+ cytotoxic T cells [1.2.1, 1.4.4]. The peptide-binding groove of HLA-A*03:01 is characterized by a preference for peptides with basic amino acids (such as lysine or arginine) at the C-terminus [1.2.1, 1.2.3]. This molecule is a significant therapeutic target and biomarker; it is associated with susceptibility to autoimmune diseases like multiple sclerosis and is used to identify patients likely to respond to glatiramer acetate [1.3.1, 1.4.1]. In oncology, HLA-A*03:01 is a key restriction element for neoantigen-targeted therapies, including TCR-engineered T cells and bispecific antibodies targeting mutations in driver genes like PIK3CA, KRAS, and EGFR [1.1.3, 1.1.4]. Recent research also highlights its role in presenting drug-hapten-peptide complexes, expanding its potential as a target for novel immunotherapies [1.1.2].

Other names

HLA-A3HLA-A*03HLA-A*0301MHC class I antigen A*03:01HLA-A*03:01 peptide-binding grooveAntigen-binding cleft of HLA-A*03:01

HLA-A*03:01 functions as a restriction element that presents specific antigenic peptides to T-cell receptors (TCRs). In multiple sclerosis, it serves as a predictive biomarker for glatiramer acetate, which modulates T-cell responses restricted by this allele [1.3.1, 1.3.3]. In oncology, it presents neoantigens (e.g., from PIK3CA, KRAS, or EGFR mutations) that are targeted by engineered TCR-T cells or bispecific antibodies, which bind the peptide-HLA complex to induce cytotoxic T-cell activity against tumor cells [1.1.3, 1.1.4, 1.4.2].